The Association for Clinical Oncology (Association) is governed by a volunteer Board of Directors , which works to ensure that the Association achieves its mission and vision.  Voting Board members are cancer physicians and clinical researchers who volunteer their time. View the Disclosures at the bottom of each individual’s bio. Please direct any questions related to Board members' disclosures to COI@asco.org.

Chair of the Association Board

Howard A. Burris III, MD, FASCO, FACP
View current ASCO disclosure here.

Howard A. "Skip" Burris III, MD, FACP, FASCO, serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for the research institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.

Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first in human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In 1997, he established in Nashville the first community based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts. Sarah Cannon has now dosed over 350 first in human anticancer therapies and enrolls more than 3000 patients per year into clinical trials.

Dr. Burris will serve as the elected president of ASCO in 2019-2020. He also currently serves on the Board of ASCO’s Conquer Cancer Foundation. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.

Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.

Association Treasurer

Julie Vose, MD, MBA, FASCO
View current ASCO disclosure here.

Dr. Vose is the Neumann M. and Mildred E. Harris Professor and Chief in the Division of Oncology/Hematology at UNMC. Dr. Vose received her medical degree, completed her residency in Internal Medicine, served as Chief Resident, and completed a Fellowship in Hematology/Oncology at UNMC. Dr. Vose also completed a sabbatical at Stanford University. In addition, she completed an MBA in Health Administration through the University of Colorado Business School. Dr. Vose has focused her career on translational research for improvement in the therapy of non-Hodgkin’s lymphoma (NHL), Hodgkin lymphoma (HL), and Chronic Lymphocytic Leukemia (CLL) by developing a focused translational research program evaluating novel therapies such as monoclonal antibodies, immunotherapy, pathway directed agents, stem cell transplantation, and chimeric antigen receptor T-cell (CAR-T) treatments. Dr. Vose has been recognized for her NHL research on a national and international level through research awards and invited lectureships worldwide. In addition, her funding record and publications in NHL therapy and transplantation research have added substantially to the research and knowledge base for the therapy of lymphoma. She was the 2015-16 President of the American Society of Clinical Oncology (ASCO).

Board Member

A. William Blackstock, MD, FASCO
View current ASCO disclosure here.

A. William Blackstock, MD, FASCO  is Professor and Chair of the Department of Radiation Oncology at the Wake Forest University (WFU) School of Medicine and Director of the Clinical Research Program at the Comprehensive Cancer Center at Wake Forest Baptist Medical Center. He received his undergraduate degree from WFU and his medical degree from the East Caroline University Brody School of Medicine. He completed a residency in radiation oncology at the University of North Carolina at Chapel Hill and a three-year NCI-funded fellowship in translational Radiation Oncology. He has been Chair at WFU for the past 8 years.

Dr. Blackstock remains active in translational clinical research, having served as vice-chair of the GI Committee in the Alliance/CALGB cooperative group and co-vice chair of the Radiation Oncology committee. In addition to serving on the NCI Clinical Oncology study section (2003-2006), he served on the NCI Pancreatic Task Force, Gastrointestinal Steering committee and co-chair of the Thoracic Malignancy Steering Committee (2013-2016). He recently completed service on the NCI Board of Scientific Counsel Intramural Program.

Dr. Blackstock has been an active ASCO member for almost 20 years, serving on the grants selection and communications committees. He has chaired the Gastrointestinal Cancer Program subcommittee and the ASCO membership committee (2008-2009). Other activities include participating in the ASCO Leadership Development Working Group and Health Disparities Advisory Group. He is currently serving as a member of the Association for Clinical Oncology Board of Directors.

Dr. Blackstock has been the lead investigator of several NCI-funded grants including principal investigator of an NCI-funded T32 fellowship focused on Translational Radiation Oncology. He currently serves on the external advisory board for several NCI/NIH funded training programs. He has published over 100 peer-reviewed manuscripts and book chapters and continues to serve on the editorial board for several journals including the Journal of Clinical Oncology (2007-2009).

Board Member

Lee M. Ellis, MD, FACS, FASCO
View current ASCO disclosure here.

Dr. Ellis is the Ruben Distinguished Chair in Gastroenterology Cancer Research and a professor in the Departments of Surgical Oncology, and Molecular & Cellular Oncology at The University of Texas MD Anderson Cancer Center (MDACC), Executive Director for Translational Research, Global Academic Programs (MDACC), as well as the Vice Chair of Translational Medicine at SWOG. Previously, he served as Interim Chair, Department of Cancer Biology from 2008 to 2012, Director of the Metastasis Research Center from 2010 to 2012, and Director of the Colorectal Cancer Translational Research Program from 2007 to 2013, all at MDACC.

Since joining ASCO in 1994, Dr. Ellis has served on numerous committees with recent committee service on the Nominating Committee (2013-2016; chair, 2015-2016), the Best Practices in Clinical Cancer Trials Workshop (2015-2016), the Cancer Research Committee (2011-2014; chair 2012-3013), and the Cancer Education Committee (2011-2013; Tumor Biology track leader, 2012-2013). He served as a faculty member of the ASCO/AACR Methods in Clinical Cancer Research Workshop in 2007-2013 and was co-director in 2010-2013. He was named a Fellow of ASCO (FASCO) in 2014, and he currently serves as the ASCO Board Liaison to the Society’s Research Committee. He is also a member of the Association for Clinical Oncology Board of Directors and the Association Board’s Executive Committee.

In addition to his ASCO involvement, Dr. Ellis serves as the co-chair of the National Cancer Institute's (NCI) National Clinical Trials Network Core Correlative Sciences Committee (NCTN-CCSC), Vice Chair emeritus of the NCI Colon Cancer Task Force, and recently completed his term as Vice Chair of the Hope Foundation, SWOG’s philanthropic arm. He also serves on the board of directors of the Canines-N-Kids Foundation. Dr. Ellis has a special interest in preclinical data reproducibility, and has published several important manuscripts in this area. He has also met with NCI, NIH, and National Academies of Science (NAS) leaders regarding the importance of this issue and how to address this problem. Dr. Ellis has also served on a NAS committee that focused on issuing recommendations to decrease the regulatory burden of research (2014-2016), and as faculty and then co-director (2015-present) of the AACR-EORTC-ESMO workshop on Methods in Clinical Cancer Research in Europe. In 2017, Dr. Ellis received the Flance-Karl Award from the American Surgical Association for his “seminal contributions in understanding colorectal cancer biology.” He currently serves on several data safety monitoring committees, including the ECOG/ACRIN DMC, and he is a member the Scientific Audit Committee of the EORTC (Brussels, Belgium), and a member of the organizing committee for ESMO’s Targeted Anti-Cancer Therapy (TAT) Annual Meeting.

Dr. Ellis received his medical degree from the University of Virginia; he performed his residency at the University of Florida, and his fellowship at MDACC.

Read Dr. Ellis’ Q&A on ASCO Connection.

Board Member

Laurie E. Gaspar, MD, MBA, FASTRO, FACR, FASCO
View current ASCO disclosure here.

Laurie E. Gaspar, MD, MBA, FASTRO, FACR, FASCO, grew up in Toronto, Ontario and completed medical school and a residency in radiation oncology at Western University. Later, after moving to the United States she completed her Masters of Business Administration (MBA) at the University of Michigan.

Dr. Gaspar has been active in many national and international committees, including the ASCO Publications Committee and ASCO’s Annual Program Committees. She is also involved with the American Board of Radiology (ABR), the American Society for Radiation Oncology (ASTRO), NRG (formally RTOG), the International Society for the Study of Lung Cancer (IASLC), and SWOG. She is a Co-Chair of the NCI Thoracic Malignancy Steering Committee. Dr. Gaspar is on the editorial board of Clinical Lung Cancer and Advances in Radiation Oncology. She is the author of more than 200 published articles.

Dr. Gaspar was Professor and Chair of the Department of Radiation Oncology at the University of Colorado for more than 15 years. She is currently Professor Emerita in the Department of Radiation Oncology at the University of Colorado, as well as a staff radiation oncologist at Banner MDA in Northern Colorado. Dr. Gaspar maintains a long-standing interest in the management of brain tumors and lung cancer.

Board Member

Charles F. Miller, MD, FACP
View current ASCO disclosure here.

Dr. Miller currently serves as Program Director for Kaiser Hawaii’s Medical Aid in Dying Program and holds a clinical appointment to the University of Hawaii Cancer Center. He has served on the Hawaii Society of Clinical Oncology Board of Directors since 2002 and served as President for seven of those years. He is actively involved at the national level with the American Society of Clinical Oncology having served on the Clinical Practice Committee, Government Relations Committee, State Affiliate Council – currently serving as Chair – and has actively participated in all of ASCO’s Advocacy Summits.

Board Member

Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO
View current ASCO disclosure here.

Dr. Mittendorf is the Rob and Karen Hale Distinguished Chair in Surgical Oncology at Brigham and Women’s Hospital, Associate Chair of Research for the Department of Surgery, and co-leader of the Breast Program at Dana-Farber / Harvard Cancer Center. She has previously served on ASCO’s Annual Meeting Scientific Program Committee and as chair of the Conquer Cancer Grants Selection Committee and chair of the ASCO-SITC Clinical Immuno-Oncology Symposium Scientific Program Committee. Dr. Mittendorf is currently the Treasurer-Elect and will serve as the Treasurer of the Society Board of Directors beginning June 2022.

Board Member

Tony S. K. Mok, BMSc, MD, FRCP(C), FRCP (Edin.), FHKCP, FHKAM (Medicine), FASCO
View current ASCO disclosure here.

Tony Mok, BMSc, MD, FRCP(C), FRCP (Edin.), FHKCP, FHKAM (Medicine), FASCO, iwas trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Canada. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career. He is Li Shu Fan Medical Foundation Named Professor of Clinical Oncology and Chair of Clinical Oncology at The Chinese University of Hong Kong (Hong Kong). His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

Prof. Mok has contributed to over 220 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is active and experienced in serving the academic societies. He is now Fellow of American Society of Clinical Oncology (FASCO), Past Chair of the ASCO International Affairs Committee, Treasurer and Past President of the International Association for the Study of Lung Cancer (IASLC), a member of the Association for Clinical Oncology Board of Directors and Vice Secretary of the Chinese Society of Clinical Oncology (CSCO).

He is closely affiliated with the oncology community in China, and has received an Honorary Professorship at Guang Dong Province People’s Hospital, Guest Professorship at Peking University School of Oncology, Visiting Professorship at Shanghai Jiao Tong University and West China School of Medicine/West China Hospital, Sichuan University. He is an Associate Editor on Thoracic Oncology for Journal of Clinical Oncology. He has also authored eight books in Chinese and hosted three television series in Hong Kong.

Board Member

Lori J. Pierce, MD, FASTRO, FASCO
View current ASCO disclosure here.

Lori J. Pierce, MD, FASTRO, FASCO is a radiation oncologist, professor, and Vice Provost for Academic and Faculty Affairs at the University of Michigan. She is also director of the Michigan Radiation Oncology Quality Consortium. A national leader in breast cancer research, Dr. Pierce was previously a Senior Investigator at the National Cancer Institute, National Institutes of Health and in 1992, joined the faculty at the University of Michigan where she has focused her career primarily on the treatment of breast cancer.

An active ASCO member since 1992, Dr. Pierce is a past member of multiple ASCO committees including the Government Relations Committee, Annual Meeting Scientific Program Committee and the Conquer Cancer Foundation Nominating Committee, and she served as a mentor for the Leadership Development Program from 2015 to 2018. She previously served on the ASCO Board of Directors from 2010 – 2014 and was named a Fellow of ASCO (FASCO) in 2015.

With over 180 manuscripts and book chapters published, Dr. Pierce has received numerous teaching and leadership awards including the American Association of Women Radiologoists’ Marie Curie Award and the Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. In 2018, she was elected into the National Academy of Medicine. Most recently, Dr. Pierce was selected as the 2019 Woman of the Year by the United Way of Washtenaw County (UWWC) of Michigan.

Dr. Pierce completed her undergraduate degree in biomedical engineering at the University of Pennsylvania and her medical degree at Duke University. She completed her internship at the Thomas Jefferson University Hospital and her residency and chief residency in Radiation Oncology at the University of Pennsylvania.

Board Member

Everett E. Vokes, MD, FASCO
View current ASCO disclosure here.

Everett E. Vokes, MD, FASCO is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medicine and Biological Sciences. He is the former leader of the Respiratory Committee of the Alliance (formerly Cancer and Leukemia Group B) and serves on the editorial boards of several journals. He is a past chair of the Annual Meeting Education Committee, Annual Meeting Scientific Program Committee, a member of the Conquer Cancer Development and Fundraising Committee, and a member of the Cancer.Net Editorial Board. He served as an elected member of the ASCO Nominating Committee, and on the Board of Directors from 2009-2012.

Board Member

Tracey F. Weisberg, MD, FASCO
View current ASCO disclosure here.

Dr. Weisberg is the past president and lead physician of New England Cancer Specialists for the past 10 years, manages an active breast cancer practice, has been a principal investigator on 40 clinical trials, and oversees medical house staff at the Maine Medical Center Oncology inpatient unit. An active member of ASCO since 1990, Dr. Weisberg is a past chair of the State Affiliate Council and has been involved in a number of ASCO initiatives, including the ASCO Rural Task Force, the CancerLinQ Advisory Committee, the Strategic Planning Task Force, and the Payment Reform Implementation Workgroup, to name a few. She is also currently a member of the Association for Clinical Oncology Board of Directors. Outside of ASCO, Dr. Weisberg has have served as a board member with Hospice of Southern Maine as well as Northern New England Oncology Association.

Read Dr. Weisberg’s Q&A on ASCO Connection.

Board Member

Eric P. Winer, MD, FASCO
View current ASCO disclosure here.

Dr. Winer has been elected to serve as the ASCO President in 2022-2023. He is the chief clinical development officer, senior vice president for medical affairs, chief of the Division of Breast Oncology, and the Thompson Chair in Breast Cancer Research at Dana-Farber Cancer Institute. He is also a professor of medicine at Harvard Medical School. Dr. Winer served on the ASCO Board of Directors from 2011 to 2015, and has served as chair of the ASCO Government Relations Committee, Cancer Communications Committee, and Health Services Research Committee, among numerous volunteer roles. He is the 2017 recipient of ASCO’s Gianni Bonadonna Breast Cancer Award and Lecture.

Non-Voting Board Member- Chief Executive Officer

Clifford A. Hudis, MD, FACP, FASCO
View current ASCO disclosure here.

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice Chair of its Conquer Cancer Foundation and Chair of ASCO’s CancerLinQ. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society’s 50th anniversary year (2013-14). Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board’s strategic goals through education, research, and support for the delivery of the highest quality of care by the Society’s nearly 45,000 members.